For press inquiries click here to contact us.
Aimmune Therapeutics, Inc.
It’s not perfect, but it’s a good start: FDA panelists largely endorse Aimmune’s peanut allergy therapy
10X Genomics
10x Genomics’ IPO rockets past a $390M raise
VenatoRx Pharmaceuticals, Inc.
VC-backed VenatoRx beefs up team with three new hires
Oric Pharmaceuticals, Inc.
New exec team, new money and a big syndicate — ORIC heads to PhII
insitro
Biotech Insitro boosts executive team with Aimmune development chief and Pfizer vet
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies stock soars 90% after ringing Nasdaq opening bell following $300M IPO
insitro
With $150M and a new NASH discovery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world
Alder Biopharmaceuticals, Inc.
Alder BioPharmaceuticals raises $170M in stock offering as FDA reviews its migraine therapy
Audentes, Inc.
Audentes Therapeutics to develop gene therapies for two types of muscular dystrophy, including Duchenne
Please see important disclaimers in the Terms section.
